Grace Therapeutics (GRCE) Long-Term Deferred Tax (2024 - 2026)

Grace Therapeutics has disclosed Long-Term Deferred Tax across 3 years of filings, most recently posting $51.1 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 18.78% year-over-year to $51.1 million; the TTM figure through Mar 2026 stood at $51.1 million (up 18.78% YoY), while the FY2026 annual figure was $51.1 million, up 18.78% from the prior year.
• Long-Term Deferred Tax came in at $51.1 million for Q1 2026 at Grace Therapeutics, up from $43.0 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $51.1 million in Q1 2026 to a low of $5.9 million in Q1 2024.
• Average Long-Term Deferred Tax over 3 years is $33.3 million, with a median of $43.0 million recorded in 2025.
• Year-over-year, Long-Term Deferred Tax jumped 635.25% in 2025 and advanced 18.78% in 2026.
• Over 3 years, Long-Term Deferred Tax stood at $5.9 million in 2024, then jumped by 635.25% to $43.0 million in 2025, then climbed by 18.78% to $51.1 million in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $51.1 million in Q1 2026, $43.0 million in Q1 2025, and $5.9 million in Q1 2024.